Tackling Cell And Gene Therapies' Top 3 Regulatory Impediments
Cell & Gene Live's first event of 2023 welcomed Dr. Adora Ndu, Chief Regulatory Affairs Officer at BridgeBio and Dr. Nina Hunter, Vice President, Corporate Strategy at REGENXBIO joining host Erin Harris to discuss the top three regulatory issues stymying the cell and gene therapy sector. Despite the promise of cell and gene therapies, the regulations governing them seem to lag, hindering the clinical translation of these novel medicines. During the hour, they discussed problems in the industry, specific FDA initiatives to overcome these, broader regulatory trends, and more.
VIEW THE VIRTUAL EVENT! Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene X
Subscribe to Cell & Gene